CYC-140 is under clinical development by Cyclacel Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CYC-140’s likelihood of approval (LoA) and phase transition for Metastatic Biliary Tract Cancer took place on 05 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CYC-140 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CYC-140 overview

CYC140 is under development for the treatment of solid tumors including triple negative breast cancer, esophageal cancer, colorectal cancer, myelodysplastic syndrome and blood cancer including chronic lymphoblastic leukemia (CLL), relapsed/refractory acute myeloblastic leukemia, relapsed/refractory leukemias, small-cell lung cancer, non-small cell lung cancer, bladder cancer, hepatocellular carcinoma, metastatic biliary tract cancer, diffuse large b-cell lymphoma, cutaneous t-cell lymphoma, peripheral t-cell lymphomas, ovarian cancer, prostate cancer, cholangiocarcinoma, gall bladder cancer and pancreatic cancer. It is a small molecule administered through oral and intravenous route. It acts by targeting polo-like kinase 1 (Plk1). Polo-like kinases play critical roles during multiple stages of cell cycle progression. Polo-like kinase (PLK) inhibitors targets the mitotic phase of the cell cycle. The drug candidate is based on genomic technology.

Cyclacel Pharmaceuticals overview

Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. Cyclacel seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

Quick View CYC-140 LOA Data

Report Segments
  • Innovator
Drug Name
  • CYC-140
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.